https://www.onhealthcare.tech/p/profluent-gemmabio-and-arpa-hs-160Thoughts on Healthcare Markets & Technologyen2026-07-12T17:28:38+00:00Profluent, GEMMABio, and ARPA-H’s 160 Million Base Editor Moonshot: Why the AI-Designed Editor Was Never the Bottleneck and the FDA’s Plausible Mechanism Pathway Is the Real Bethttps://www.onhealthcare.tech/p/profluent-gemmabio-and-arpa-h-s-160Thoughts on Healthcare Markets & Technologyen2026-07-12T16:57:29+00:00Profluent, GEMMABio, and ARPA-H ‘s 160 Million Base Editor Moonshot: Why the AI-Designed Editor Was Never the Bottleneck and the FDA’s Plausible Mechanism Pathway Is the Real Bethttps://www.onhealthcare.tech/p/biomni-and-the-code-executing-biomedical-286Thoughts on Healthcare Markets & Technologyen2026-07-11T11:36:16+00:00Biomni and the Code-Executing Biomedical Agent: What Happens to Drug Discovery, Clinical Genomics, and the Price of Scientific Labor When the Model Can Actually Run the Workflowhttps://www.onhealthcare.tech/p/biomni-and-the-code-executing-biomedicalThoughts on Healthcare Markets & Technologyen2026-07-11T11:29:24+00:00Biomni and the Code-Executing Biomedical Agent: What Happens to Drug Discovery, Clinical Genomics, and the Price of Scientific Labor When the Model Can Actually Run the Workflow